Parsaclisib Not Yet Recruiting Phase 3 Trials for Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) / Myelofibrosis / Primary Myelofibrosis (PMF) / Post Polycythemia Vera Myelofibrosis Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT04816565To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)